Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 167

1.

Histone H2AX promotes neuronal health by controlling mitochondrial homeostasis.

Weyemi U, Paul BD, Bhattacharya D, Malla AP, Boufraqech M, Harraz MM, Bonner WM, Snyder SH.

Proc Natl Acad Sci U S A. 2019 Apr 9;116(15):7471-7476. doi: 10.1073/pnas.1820245116. Epub 2019 Mar 25.

PMID:
30910969
2.

Anti-tumour effects of all-trans retinoid acid on serous ovarian cancer.

Lokman NA, Ho R, Gunasegaran K, Bonner WM, Oehler MK, Ricciardelli C.

J Exp Clin Cancer Res. 2019 Jan 8;38(1):10. doi: 10.1186/s13046-018-1017-7.

3.

Morphometric and gene expression analyses of stromal expansion during development of the bovine fetal ovary.

Hartanti MD, Hummitzsch K, Irving-Rodgers HF, Bonner WM, Copping KJ, Anderson RA, McMillen IC, Perry VEA, Rodgers RJ.

Reprod Fertil Dev. 2019 Mar;31(3):482-495. doi: 10.1071/RD18218.

PMID:
30501845
4.

Histone H2AX deficiency causes neurobehavioral deficits and impaired redox homeostasis.

Weyemi U, Paul BD, Snowman AM, Jailwala P, Nussenzweig A, Bonner WM, Snyder SH.

Nat Commun. 2018 Apr 18;9(1):1526. doi: 10.1038/s41467-018-03948-9.

5.

Novel ex vivo ovarian cancer tissue explant assay for prediction of chemosensitivity and response to novel therapeutics.

Ricciardelli C, Lokman NA, Sabit I, Gunasegaran K, Bonner WM, Pyragius CE, Macpherson AM, Oehler MK.

Cancer Lett. 2018 May 1;421:51-58. doi: 10.1016/j.canlet.2018.02.006. Epub 2018 Feb 6.

PMID:
29425684
6.

Phase I trial of belinostat with cisplatin and etoposide in advanced solid tumors, with a focus on neuroendocrine and small cell cancers of the lung.

Balasubramaniam S, Redon CE, Peer CJ, Bryla C, Lee MJ, Trepel JB, Tomita Y, Rajan A, Giaccone G, Bonner WM, Figg WD, Fojo T, Piekarz RL, Bates SE.

Anticancer Drugs. 2018 Jun;29(5):457-465. doi: 10.1097/CAD.0000000000000596.

PMID:
29420340
7.

Replication Stress Shapes a Protective Chromatin Environment across Fragile Genomic Regions.

Kim J, Sturgill D, Sebastian R, Khurana S, Tran AD, Edwards GB, Kruswick A, Burkett S, Hosogane EK, Hannon WW, Weyemi U, Bonner WM, Luger K, Oberdoerffer P.

Mol Cell. 2018 Jan 4;69(1):36-47.e7. doi: 10.1016/j.molcel.2017.11.021. Epub 2017 Dec 14.

8.

Histone variant H2A.J accumulates in senescent cells and promotes inflammatory gene expression.

Contrepois K, Coudereau C, Benayoun BA, Schuler N, Roux PF, Bischof O, Courbeyrette R, Carvalho C, Thuret JY, Ma Z, Derbois C, Nevers MC, Volland H, Redon CE, Bonner WM, Deleuze JF, Wiel C, Bernard D, Snyder MP, Rübe CE, Olaso R, Fenaille F, Mann C.

Nat Commun. 2017 May 10;8:14995. doi: 10.1038/ncomms14995.

9.

p21: A Two-Faced Genome Guardian.

Georgakilas AG, Martin OA, Bonner WM.

Trends Mol Med. 2017 Apr;23(4):310-319. doi: 10.1016/j.molmed.2017.02.001. Epub 2017 Mar 7. Review.

PMID:
28279624
10.

The Causal Relationship between DNA Damage Induction in Bovine Lymphocytes and the Fukushima Nuclear Power Plant Accident.

Nakamura AJ, Suzuki M, Redon CE, Kuwahara Y, Yamashiro H, Abe Y, Takahashi S, Fukuda T, Isogai E, Bonner WM, Fukumoto M.

Radiat Res. 2017 May;187(5):630-636. doi: 10.1667/RR14630.1. Epub 2017 Feb 27.

11.

Phosphorylated fraction of H2AX as a measurement for DNA damage in cancer cells and potential applications of a novel assay.

Ji J, Zhang Y, Redon CE, Reinhold WC, Chen AP, Fogli LK, Holbeck SL, Parchment RE, Hollingshead M, Tomaszewski JE, Dudon Q, Pommier Y, Doroshow JH, Bonner WM.

PLoS One. 2017 Feb 3;12(2):e0171582. doi: 10.1371/journal.pone.0171582. eCollection 2017.

12.

Evaluation of surrogate tissues as indicators of drug activity in a melanoma skin model.

Parekh PR, Choudhuri R, Weyemi U, Martin OA, Bonner WM, Redon CE.

Cancer Med. 2016 Aug;5(8):1731-41. doi: 10.1002/cam4.726. Epub 2016 Jun 23.

13.

Twist1 and Slug mediate H2AX-regulated epithelial-mesenchymal transition in breast cells.

Weyemi U, Redon CE, Sethi TK, Burrell AS, Jailwala P, Kasoji M, Abrams N, Merchant A, Bonner WM.

Cell Cycle. 2016 Sep 16;15(18):2398-404. doi: 10.1080/15384101.2016.1198864. Epub 2016 Jun 17.

14.

Regulation of fibrillins and modulators of TGFβ in fetal bovine and human ovaries.

Bastian NA, Bayne RA, Hummitzsch K, Hatzirodos N, Bonner WM, Hartanti MD, Irving-Rodgers HF, Anderson RA, Rodgers RJ.

Reproduction. 2016 Aug;152(2):127-37. doi: 10.1530/REP-16-0172. Epub 2016 May 24.

PMID:
27222596
15.

Clinical and pharmacologic evaluation of two dosing schedules of indotecan (LMP400), a novel indenoisoquinoline, in patients with advanced solid tumors.

Kummar S, Chen A, Gutierrez M, Pfister TD, Wang L, Redon C, Bonner WM, Yutzy W, Zhang Y, Kinders RJ, Ji J, Allen D, Covey JM, Eiseman JL, Holleran JL, Beumer JH, Rubinstein L, Collins J, Tomaszewski J, Parchment R, Pommier Y, Doroshow JH.

Cancer Chemother Pharmacol. 2016 Jul;78(1):73-81. doi: 10.1007/s00280-016-2998-6. Epub 2016 May 11.

16.

Effects of Breast Shielding during Heart Imaging on DNA Double-Strand-Break Levels: A Prospective Randomized Controlled Trial.

Cheezum MK, Redon CE, Burrell AS, Kaviratne AS, Bindeman J, Maeda D, Balmakhtar H, Pezel A, Wisniewski P, Delacruz P, Nguyen B, Bonner WM, Villines TC.

Radiology. 2016 Oct;281(1):62-71. doi: 10.1148/radiol.2016152301. Epub 2016 Apr 15.

17.

H2AX and EMT: deciphering beyond DNA repair.

Weyemi U, Redon CE, Bonner WM.

Cell Cycle. 2016 May 18;15(10):1305-6. doi: 10.1080/15384101.2016.1160659. Epub 2016 Mar 17. No abstract available.

18.

The histone variant H2A.X is a regulator of the epithelial-mesenchymal transition.

Weyemi U, Redon CE, Choudhuri R, Aziz T, Maeda D, Boufraqech M, Parekh PR, Sethi TK, Kasoji M, Abrams N, Merchant A, Rajapakse VN, Bonner WM.

Nat Commun. 2016 Feb 15;7:10711. doi: 10.1038/ncomms10711.

19.

90Y-daclizumab, an anti-CD25 monoclonal antibody, provided responses in 50% of patients with relapsed Hodgkin's lymphoma.

Janik JE, Morris JC, O'Mahony D, Pittaluga S, Jaffe ES, Redon CE, Bonner WM, Brechbiel MW, Paik CH, Whatley M, Chen C, Lee JH, Fleisher TA, Brown M, White JD, Stewart DM, Fioravanti S, Lee CC, Goldman CK, Bryant BR, Junghans RP, Carrasquillo JA, Worthy T, Corcoran E, Conlon KC, Waldmann TA.

Proc Natl Acad Sci U S A. 2015 Oct 20;112(42):13045-50. doi: 10.1073/pnas.1516107112. Epub 2015 Oct 5.

20.

Evidence for chromosome fragility at the frataxin locus in Friedreich ataxia.

Kumari D, Hayward B, Nakamura AJ, Bonner WM, Usdin K.

Mutat Res. 2015 Nov;781:14-21. doi: 10.1016/j.mrfmmm.2015.08.007. Epub 2015 Aug 30.

21.

Localization of the Trace Elements Iron, Zinc and Selenium in Relation to Anatomical Structures in Bovine Ovaries by X-Ray Fluorescence Imaging.

Ceko MJ, Hummitzsch K, Bonner WM, Aitken JB, Spiers KM, Rodgers RJ, Harris HH.

Microsc Microanal. 2015 Jun;21(3):695-705. doi: 10.1017/S1431927615000380. Epub 2015 Apr 8.

PMID:
25850937
22.

Inactivation of NADPH oxidases NOX4 and NOX5 protects human primary fibroblasts from ionizing radiation-induced DNA damage.

Weyemi U, Redon CE, Aziz T, Choudhuri R, Maeda D, Parekh PR, Bonner MY, Arbiser JL, Bonner WM.

Radiat Res. 2015 Mar;183(3):262-70. doi: 10.1667/RR13799.1. Epub 2015 Feb 23.

23.

NADPH oxidase 4 is a critical mediator in Ataxia telangiectasia disease.

Weyemi U, Redon CE, Aziz T, Choudhuri R, Maeda D, Parekh PR, Bonner MY, Arbiser JL, Bonner WM.

Proc Natl Acad Sci U S A. 2015 Feb 17;112(7):2121-6. doi: 10.1073/pnas.1418139112. Epub 2015 Feb 2.

24.

A phase i study of DMS612, a novel bifunctional alkylating agent.

Appleman LJ, Balasubramaniam S, Parise RA, Bryla C, Redon CE, Nakamura AJ, Bonner WM, Wright JJ, Piekarz R, Kohler DR, Jiang Y, Belani CP, Eiseman J, Chu E, Beumer JH, Bates SE.

Clin Cancer Res. 2015 Feb 15;21(4):721-9. doi: 10.1158/1078-0432.CCR-14-1333. Epub 2014 Dec 2.

25.

Correction: X-Ray fluorescence imaging and other analyses identify selenium and GPX1 as important in female reproductive function.

Ceko MJ, Hummitzsch K, Hatzirodos N, Bonner WM, Aitken JB, Russell DL, Lane M, Rodgers RJ, Harris HH.

Metallomics. 2015 Jan;7(1):188. doi: 10.1039/c4mt90049a. Epub 2014 Nov 27.

PMID:
25427852
26.

X-Ray fluorescence imaging and other analyses identify selenium and GPX1 as important in female reproductive function.

Ceko MJ, Hummitzsch K, Hatzirodos N, Bonner WM, Aitken JB, Russell DL, Lane M, Rodgers RJ, Harris HH.

Metallomics. 2015 Jan;7(1):71-82. doi: 10.1039/c4mt00228h. Epub 2014 Nov 3. Erratum in: Metallomics. 2015 Jan;7(1):188.

PMID:
25362850
27.

Systemic DNA damage accumulation under in vivo tumor growth can be inhibited by the antioxidant Tempol.

Georgakilas AG, Redon CE, Ferguson NF, Kryston TB, Parekh P, Dickey JS, Nakamura AJ, Mitchell JB, Bonner WM, Martin OA.

Cancer Lett. 2014 Oct 28;353(2):248-57. doi: 10.1016/j.canlet.2014.07.030. Epub 2014 Jul 25.

28.

Evaluation of the gamma-H2AX assay for radiation biodosimetry in a swine model.

Moroni M, Maeda D, Whitnall MH, Bonner WM, Redon CE.

Int J Mol Sci. 2013 Jul 8;14(7):14119-35. doi: 10.3390/ijms140714119.

29.

Susceptibility to bystander DNA damage is influenced by replication and transcriptional activity.

Dickey JS, Baird BJ, Redon CE, Avdoshina V, Palchik G, Wu J, Kondratyev A, Bonner WM, Martin OA.

Nucleic Acids Res. 2012 Nov 1;40(20):10274-86. doi: 10.1093/nar/gks795. Epub 2012 Aug 31.

30.

NADPH Oxidases NOXs and DUOXs as putative targets for cancer therapy.

Weyemi U, Redon CE, Parekh PR, Dupuy C, Bonner WM.

Anticancer Agents Med Chem. 2013 Mar;13(3):502-14. Review.

31.

A unified phylogeny-based nomenclature for histone variants.

Talbert PB, Ahmad K, Almouzni G, Ausió J, Berger F, Bhalla PL, Bonner WM, Cande WZ, Chadwick BP, Chan SW, Cross GA, Cui L, Dimitrov SI, Doenecke D, Eirin-López JM, Gorovsky MA, Hake SB, Hamkalo BA, Holec S, Jacobsen SE, Kamieniarz K, Khochbin S, Ladurner AG, Landsman D, Latham JA, Loppin B, Malik HS, Marzluff WF, Pehrson JR, Postberg J, Schneider R, Singh MB, Smith MM, Thompson E, Torres-Padilla ME, Tremethick DJ, Turner BM, Waterborg JH, Wollmann H, Yelagandula R, Zhu B, Henikoff S.

Epigenetics Chromatin. 2012 Jun 21;5:7. doi: 10.1186/1756-8935-5-7.

32.

Enhanced intrinsic radiosensitivity after treatment with stereotactic radiosurgery for an acoustic neuroma.

Adams G, Martin OA, Roos DE, Lobachevsky PN, Potter AE, Zacest AC, Bezak E, Bonner WM, Martin RF, Leong T.

Radiother Oncol. 2012 Jun;103(3):410-4. doi: 10.1016/j.radonc.2012.03.011. Epub 2012 May 3.

PMID:
22560711
33.

γ-H2AX and other histone post-translational modifications in the clinic.

Redon CE, Weyemi U, Parekh PR, Huang D, Burrell AS, Bonner WM.

Biochim Biophys Acta. 2012 Jul;1819(7):743-56. doi: 10.1016/j.bbagrm.2012.02.021. Epub 2012 Mar 9. Review.

34.

SOD2 deficiency promotes aging phenotypes in mouse skin.

Weyemi U, Parekh PR, Redon CE, Bonner WM.

Aging (Albany NY). 2012 Feb;4(2):116-8. Review. No abstract available.

35.

High salt and DNA double-strand breaks.

Redon CE, Bonner WM.

Proc Natl Acad Sci U S A. 2011 Dec 20;108(51):20281-2. doi: 10.1073/pnas.1117713109. Epub 2011 Dec 12. No abstract available.

36.

Q(γ-H2AX), an analysis method for partial-body radiation exposure using γ-H2AX in nonhuman primate lymphocytes.

Redon CE, Nakamura AJ, Gouliaeva K, Rahman A, Blakely WF, Bonner WM.

Radiat Meas. 2011 Sep 1;46(9):877-881.

37.

Systemic DNA damage related to cancer.

Martin OA, Redon CE, Nakamura AJ, Dickey JS, Georgakilas AG, Bonner WM.

Cancer Res. 2011 May 15;71(10):3437-41. doi: 10.1158/0008-5472.CAN-10-4579. Epub 2011 May 10. Review.

38.

Para-inflammation mediates systemic DNA damage in response to tumor growth.

Martin OA, Redon CE, Dickey JS, Nakamura AJ, Bonner WM.

Commun Integr Biol. 2011 Jan;4(1):78-81. doi: 10.4161/cib.4.1.13942.

39.

Recent developments in the use of γ-H2AX as a quantitative DNA double-strand break biomarker.

Redon CE, Nakamura AJ, Martin OA, Parekh PR, Weyemi US, Bonner WM.

Aging (Albany NY). 2011 Feb;3(2):168-74.

40.

γH2AX foci as a measure of DNA damage: a computational approach to automatic analysis.

Ivashkevich AN, Martin OA, Smith AJ, Redon CE, Bonner WM, Martin RF, Lobachevsky PN.

Mutat Res. 2011 Jun 3;711(1-2):49-60. doi: 10.1016/j.mrfmmm.2010.12.015. Epub 2011 Jan 7.

41.

Hypothermia postpones DNA damage repair in irradiated cells and protects against cell killing.

Baird BJ, Dickey JS, Nakamura AJ, Redon CE, Parekh P, Griko YV, Aziz K, Georgakilas AG, Bonner WM, Martin OA.

Mutat Res. 2011 Jun 3;711(1-2):142-9. doi: 10.1016/j.mrfmmm.2010.12.006. Epub 2010 Dec 24.

PMID:
21185842
42.

H2AX phosphorylation in response to DNA double-strand break formation during bystander signalling: effect of microRNA knockdown.

Dickey JS, Zemp FJ, Altamirano A, Sedelnikova OA, Bonner WM, Kovalchuk O.

Radiat Prot Dosimetry. 2011 Feb;143(2-4):264-9. doi: 10.1093/rpd/ncq470. Epub 2010 Dec 23.

43.

The use of gamma-H2AX as a biodosimeter for total-body radiation exposure in non-human primates.

Redon CE, Nakamura AJ, Gouliaeva K, Rahman A, Blakely WF, Bonner WM.

PLoS One. 2010 Nov 23;5(11):e15544. doi: 10.1371/journal.pone.0015544.

44.

γ-H2AX detection in peripheral blood lymphocytes, splenocytes, bone marrow, xenografts, and skin.

Redon CE, Nakamura AJ, Sordet O, Dickey JS, Gouliaeva K, Tabb B, Lawrence S, Kinders RJ, Bonner WM, Sedelnikova OA.

Methods Mol Biol. 2011;682:249-70. doi: 10.1007/978-1-60327-409-8_18.

PMID:
21057933
45.

Development of a validated immunofluorescence assay for γH2AX as a pharmacodynamic marker of topoisomerase I inhibitor activity.

Kinders RJ, Hollingshead M, Lawrence S, Ji J, Tabb B, Bonner WM, Pommier Y, Rubinstein L, Evrard YA, Parchment RE, Tomaszewski J, Doroshow JH; National Cancer Institute Phase 0 Clinical Trials Team.

Clin Cancer Res. 2010 Nov 15;16(22):5447-57. doi: 10.1158/1078-0432.CCR-09-3076. Epub 2010 Oct 5.

46.

Tumors induce complex DNA damage in distant proliferative tissues in vivo.

Redon CE, Dickey JS, Nakamura AJ, Kareva IG, Naf D, Nowsheen S, Kryston TB, Bonner WM, Georgakilas AG, Sedelnikova OA.

Proc Natl Acad Sci U S A. 2010 Oct 19;107(42):17992-7. doi: 10.1073/pnas.1008260107. Epub 2010 Sep 20.

47.

Histone gammaH2AX and poly(ADP-ribose) as clinical pharmacodynamic biomarkers.

Redon CE, Nakamura AJ, Zhang YW, Ji JJ, Bonner WM, Kinders RJ, Parchment RE, Doroshow JH, Pommier Y.

Clin Cancer Res. 2010 Sep 15;16(18):4532-42. doi: 10.1158/1078-0432.CCR-10-0523. Epub 2010 Sep 7. Review.

48.

γH2AX: Applications for the evaluation of telomerase-based cancer therapy.

Nakamura AJ, Redon CE, Bonner WM.

Cell Cycle. 2010 Sep 1;9(17):3385-6. doi: 10.4161/cc.9.17.13003. Epub 2010 Sep 13. No abstract available.

PMID:
20703091
49.

microRNAome changes in bystander three-dimensional human tissue models suggest priming of apoptotic pathways.

Kovalchuk O, Zemp FJ, Filkowski JN, Altamirano AM, Dickey JS, Jenkins-Baker G, Marino SA, Brenner DJ, Bonner WM, Sedelnikova OA.

Carcinogenesis. 2010 Oct;31(10):1882-8. doi: 10.1093/carcin/bgq119. Epub 2010 Jul 19.

50.

Impact papers on aging in 2009.

Blagosklonny MV, Campisi J, Sinclair DA, Bartke A, Blasco MA, Bonner WM, Bohr VA, Brosh RM Jr, Brunet A, Depinho RA, Donehower LA, Finch CE, Finkel T, Gorospe M, Gudkov AV, Hall MN, Hekimi S, Helfand SL, Karlseder J, Kenyon C, Kroemer G, Longo V, Nussenzweig A, Osiewacz HD, Peeper DS, Rando TA, Rudolph KL, Sassone-Corsi P, Serrano M, Sharpless NE, Skulachev VP, Tilly JL, Tower J, Verdin E, Vijg J.

Aging (Albany NY). 2010 Mar;2(3):111-21. Epub 2010 Mar 23. Review.

Supplemental Content

Loading ...
Support Center